EGFR and non-small cell lung carcinoma: Since oncogenic mutations and aberrant activation of EGFR occurs frequently in various tumor types including non-small cell lung carcinomas (NSCLC) [23, 24], SFK inhibitors are currently used to treat various malignancies [25, 26].